BioVerative

Overview

Rare disease company spun out of Biogen under CEO John Cox; grew to over $1 billion in annual revenue before being acquired by Sanofi; notable for rapidly acquiring True North for $800 million just two months after launch. BioVerative was spun out of Biogen under CEO John Cox and grew to more than $1 billion in annual sales before being acquired by Sanofi. Just two months after launching BioVerative, Cox acquired True North for $800 million with only approximately $200 million in cash on hand, winning the deal over larger competitors through speed of decision-making and arranging additional financing after committing to the offer. (Segment 1 (00:00-05:00))